How should a pregnant patient who has been started on 2 mg of Suboxone (buprenorphine/naloxone) be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management of Pregnant Patient Started on 2 mg Suboxone

Continue the Suboxone (buprenorphine/naloxone) throughout pregnancy and do not attempt to wean or discontinue it, as the 2 mg dose is likely subtherapeutic and will need to be increased to achieve adequate suppression of cravings and withdrawal. 1

Immediate Dose Assessment and Titration

The current 2 mg dose is below the therapeutic range for most pregnant patients with opioid use disorder (OUD). The typical effective dose range is 4-24 mg daily, with a median of 16 mg needed to suppress illicit opioid use in pregnancy. 1

Dose Optimization Strategy:

  • Assess withdrawal symptoms using the Clinical Opiate Withdrawal Scale (COWS) and evaluate for ongoing cravings or illicit opioid use
  • Titrate upward by 2-4 mg increments based on clinical response 1
  • Target dose: Most pregnant patients require 8-20 mg daily, with many needing the dose divided into 2-3 times daily (rather than once daily) as pregnancy progresses 1, 2
  • Monitor plasma levels: Pregnancy increases buprenorphine metabolism, requiring higher and more frequent dosing compared to non-pregnant patients 1, 2

Critical Management Principles

Throughout Pregnancy:

Do not attempt detoxification or weaning before delivery - this significantly increases risk of maternal withdrawal, relapse, overdose death, and fetal/neonatal harm 1. The goals of medication-assisted treatment (MAT) in pregnancy are to:

  • Suppress cravings and withdrawal symptoms
  • Prevent illicit opioid use
  • Increase prenatal care adherence
  • Reduce infection risk from IV drug use 1

Regarding Buprenorphine/Naloxone vs Monotherapy:

Continuation of the combination product (Suboxone) is acceptable in pregnancy. 1 While buprenorphine monotherapy was historically preferred due to theoretical concerns about naloxone precipitating withdrawal, current evidence does not support this concern 1. The naloxone component has minimal systemic absorption sublingually and is not detected or only minimally detected in maternal plasma 3, 4, 5.

Interdisciplinary Care Coordination

Establish connections with:

  • Addiction medicine specialist or experienced OB provider for ongoing MAT management 1
  • Anesthesia consultation prenatally to plan labor analgesia 1
  • Behavioral health support for counseling and relapse prevention 1
  • Neonatology for anticipated neonatal opioid withdrawal syndrome (NOWS) monitoring 1

Labor and Delivery Planning

Pain Management Protocol:

  • Continue daily Suboxone dose throughout labor - do not hold or reduce 1
  • Consider splitting the dose into 2-3 administrations during labor for improved pain control 1
  • Prioritize neuraxial analgesia (epidural/combined spinal-epidural) early in labor - this is highly effective in opioid-dependent patients 1
  • Avoid opioid agonist-antagonists (nalbuphine, butorphanol) - these precipitate withdrawal 1
  • Avoid nitrous oxide - less effective and increases sedation risk 1
  • If additional opioids needed: Use full mu-receptor agonists with strong affinity (fentanyl, hydromorphone) rather than weaker opioids 1

Postpartum Pain Management:

Use multimodal analgesia (NSAIDs, acetaminophen, regional techniques). Additional systemic opioids may be necessary but should not be routine 1.

Neonatal Considerations

Anticipate NOWS (Neonatal Opioid Withdrawal Syndrome) - this is the most consistent adverse effect of buprenorphine exposure 1. However:

  • Buprenorphine-exposed neonates require less pharmacotherapy and shorter hospital stays compared to methadone-exposed infants 1, 3, 4
  • No increased risk of birth defects with buprenorphine 1, 6
  • No long-term neurodevelopmental impact when comparing exposed vs non-exposed children from similar socioeconomic backgrounds 1

Breastfeeding

Breastfeeding is safe and should be encouraged on Suboxone 5. Buprenorphine and norbuprenorphine are present in breast milk at low concentrations. Naloxone is either not detected or present at concentrations below quantification limits in breast milk and infant plasma 5.

Postpartum Continuation

Establish plans for continued MAT during the postpartum year before delivery 1. This is critical as the postpartum period carries high relapse and overdose risk. The patient will likely need dose adjustments postpartum as pregnancy-related metabolic changes resolve 1, 2.

Common Pitfalls to Avoid

  1. Underdosing: 2 mg is inadequate for most patients - assess and titrate appropriately 1
  2. Attempting to wean before delivery: This increases maternal and fetal mortality risk 1
  3. Switching to monotherapy unnecessarily: The combination product is safe in pregnancy 1, 3, 4
  4. Holding medication during labor: Continue throughout labor and delivery 1
  5. Inadequate pain management planning: Arrange anesthesia consultation prenatally 1

References

3
Research

Safety and Efficacy of Buprenorphine-Naloxone in Pregnancy: A Systematic Review of the Literature.

Pathophysiology : the official journal of the International Society for Pathophysiology, 2023

4
Research

Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis.

American journal of obstetrics & gynecology MFM, 2020

5
Research

Buprenorphine-Naloxone Maintenance and Lactation.

Journal of human lactation : official journal of International Lactation Consultant Association, 2024

Related Questions

How should a 36-year-old female with substance use disorder on methadone who presents with rectal pain, bright red blood per rectum, and constipation for more than 10 days, with a history of three cesarean sections and external hemorrhoids (gravida 5, para 3) be managed?
In a 36-year-old patient in rehab after alcohol and fentanyl detoxification, with chronic low back pain and depression treated with duloxetine 90 mg, who is now showing signs of delayed oxycodone withdrawal (red eyes without discharge, myalgias, yawning), should Suboxone (buprenorphine/naloxone) be started, and how should the induction be performed?
Is it appropriate to take Suboxone (buprenorphine/naloxone) 4 mg twice daily instead of the usual once‑daily regimen?
What is the appropriate Suboxone (buprenorphine/naloxone) dosing regimen to switch a patient from buprenorphine 6 mg twice daily (total 12 mg per day) to an equivalent regimen?
How should a 20-year-old patient with anemia, dizziness, a history of drug abuse, and current suboxone (buprenorphine/naloxone) therapy be evaluated and managed?
For a patient with an ankle sprain causing pain under the lateral malleolus that extends across the midfoot to the bases of the second and third toes six weeks after injury, what MRI protocol should be ordered and which ligaments or tendons are likely involved?
In a patient with non‑cirrhotic portal hypertension who has had an esophageal variceal bleed and also has portal vein thrombosis, should a non‑selective beta‑blocker be used?
When and how should I start dapagliflozin (an SGLT2 inhibitor) in an adult with type 2 diabetes, heart failure with reduced ejection fraction, or chronic kidney disease, including dosing and safety precautions?
Is the area under the left breast extending down the left side a dermatome consistent with shingles?
What ICD-10-CM code should be used for a malignant neoplasm of an unspecified site of the left female breast?
What is the recommended protocol for tapering and discontinuing venlafaxine in a 63‑year‑old female?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.